Sign in

You're signed outSign in or to get full access.

Jaye

Vice President and Equity Research Analyst at Citigroup

Jaye is a Vice President and Equity Research Analyst at Citigroup, specializing in the healthcare sector with a focus on biotechnology and pharmaceuticals. She covers specific companies including Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Moderna, boasting a strong performance track record with a 68% success rate on TipRanks and average return of 15.2% per rating. Jaye joined Citigroup in 2021 after previous roles at Jefferies as a research associate from 2018 to 2021 and at Leerink Partners from 2016 to 2018, following her start in equity research post-MBA. She holds Series 7, 63, and 86/87 FINRA licenses and was recognized as a Rising Star in Healthcare Research by Institutional Investor in 2023.

Jaye's questions to Scholar Rock Holding (SRRK) leadership

Question · Q4 2025

Jaye inquired if the second fill-finish facility would fully de-risk the supply chain for U.S. and EU launches, and what specific leading indicators Scholar Rock is tracking for payer and physician readiness.

Answer

David Hallal, Chairman and CEO of Scholar Rock, confirmed confidence that the second fill-finish facility, if relied upon solely, would de-risk both U.S. and EU commercial opportunities. Keith Woods, Chief Operating Officer, Scholar Rock, highlighted positive access and in-depth discussions with national and regional payers, with medical teams reviewing SAPPHIRE data, noting neurologists' and patients' desire for more SMA treatment options.

Ask follow-up questions

Fintool

Fintool can predict Scholar Rock Holding logo SRRK's earnings beat/miss a week before the call